Phase 2 N=435 Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®
Smallpox
Primary: Geometric Mean Peak Plaque Reduction Neutralization Titer (PRNT) After Second Vaccination — 138.0; 55.1; 75.9; 103.5 titers
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Iodine Impregnated Incision Drapes and Bacterial Recolonization in Simulated Knee Surgery. A Controlled Randomized Experimental Trial.
Total Knee Replacement Surgery
Primary: Bacterial Quantity — 0.26; 0.32; 0.0; 0.26 Log10 CFU/cm^2 — p=0.601
N/A N=162 Does Noninvasive Electrical Stimulation of Acupuncture Points (NESAP) Reduce Heelstick Pain in Infants?
Pain
Primary: Changes From Baseline Premature Infant Pain Profile (PIPP) Score to Average PIPP Score During Heel Stick and Squeeze. — 4.0; 5.0; 3.6; 4.9 units on a scale (PIPP score)…
Phase 4 N=206 Neo-Synalar Modified 48 Hour Patch Test
Allergy
Primary: Evidence of Pre-Existing Sensitization by Use of the Erythemal Scoring Scale (ESS) — 0 percentage of patients w allergic rxn
Phase 4 N=11 Minocycline to Treat Childhood Regressive Autism
Autism · Minocycline · Regressive Autism
Primary: z Score — -0.45; -0.36; -1.78; -0.18 Z-score
Phase 3 N=929 Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
Multiple Myeloma
Primary: Progression-free Survival — 9.4; 18.7 months — p=< 0.0001
N/A N=105 Study of the Use of Low Level Laser Light Therapy to Treat Toenail Fungus
Onychomycosis
Primary: Proportion of Toenails Attaining 25 Percent (%) or More Increase in Clear Nail — 65 percentage of toenails
Phase 4 N=100 Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
Acute Coronary Syndrome
Primary: Inhibition of the P2Y12 Receptor at 2 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by P2Y12 Reaction Units (PRU) From VerifyNow™ — 98.4; 257.5 PRU…
Phase 2 N=71 Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults
Juvenile Idiopathic Arthritis
Primary: Time to Response to Treatment, as Determined by a Modified JIA ACR30 Requiring no Fever, Coupled With a Requirement for Corticosteroid Taper in Participants Who Are…
Phase 3 N=1,086 Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer
Breast Cancer
Primary: Disease-free Survival — 74.7; 78.1 percentage of participants — p=0.14
Phase 2 N=323 A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
Kidney Transplantation
Primary: Percentage of Participants With Biopsy-confirmed Acute Rejection (BCAR) at Month 6 Assessed by Local Review — 12.7; 26.3; 18.8; 16.7 percentage of participants
N/A N=50 Effect of Tetanus on Neuromuscular Junction Monitor Performance in Pediatric Patients
Muscle Relaxation
Primary: Train of Four 0,9 (90%) — 49.9; 41.7 minutes
Phase 3 N=2,680 Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older
Influenza
Primary: 1.Geometric Mean Titres (GMT) in Subjects After Receiving One Dose of Either QIVc, TIV1c or TIV2c — 60.7; 59.6; NA; 302.8 Titer
Phase 2 N=138 4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
Epilepsy
Primary: Number of Participants With Treatment-emergent Non-serious Adverse Events (AEs) and Treatment-emergent Serious Adverse Events (SAEs) — 112; 33 Participants
Phase 3 N=124 A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma
Lymphoma, Follicular
Primary: Event-free Survival — 53.944 months